InSite Vision
Executive Summary
Plans to file amended NDA for MethaSite (extended-release fluorometholone eyedrops) in first half of 1994, company reports in Aug. 27 prospectus for an initial public offering of 3 mil. shares. MethaSite was designated approvable by FDA in March 1990 for control of mild-to-moderate inflammation in the anterior segment of the eye. The Alameda, Calif. company subsequently conducted a second Phase III trial using "the 'blow, fill, seal' manufacturing process to be used for the commercial production of MethaSite," the prospectus states. Morgan Stanley and Robertson Stephens are underwriting the offering.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth